January 14, 2021 -- Oncternal Therapeutics announced an agreement with Lentigen Technology, a subsidiary of Miltenyi Biotec, to manufacture lentiviral vectors for Octernal's investigational receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeting chimeric antigen receptor (CAR) T-cell therapy program.
Lentigen focuses on the design, construction, and production of lentiviral vectors from research through good manufacturing practice (GMP) manufacturing.
Under the agreement, Lentigen will reserve capacity in 2021 to manufacture, test, and release GMP lentivirus vectors to support and accelerate the development of Oncternal's CAR T-cell therapy program.
No financial details of the agreement were disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
